Keyword: Lars Fruergaard Jorgensen
Novo faces intense competition in diabetes, but the company can succeed with strong offerings, CEO Lars Fruergaard Jørgensen said at an event.
After Novo Nordisk secures U.S. access for Rybelsus, it'll be time to go into "strike mode" with full promotion, its CEO said.
ICER concluded that Novo Nordisk's diabetes pill Rybelsus will be less cost-effective than Jardiance as an add-on therapy in type 2 diabetes.
Big Pharma CEOs have their own way of cozying up to the world’s second largest pharmaceutical market—by getting themselves Chinese names.
Sweep out drug rebates for patient discounts instead? Supply chain players hate the idea, but Big Pharma CEOs are all over it.
Novo Nordisk rolled out more data for its next great hope: oral semaglutide, which would be the only pill in a hotly competitive GLP-1 class.
The approval case for Novo Nordisk’s oral diabetes candidate keeps on building, this time with new data in patients with kidney troubles.
Novo Nordisk expects basal insulin prices to sink even further next year—but that shouldn’t surprise investors too much, the company’s CEO says.
Let’s just say it hasn’t been a great week for Novo Nordisk.
Novo Nordisk is counting on multiple new drug launches—including the blockbuster-to-be semaglutide to help overcome market headwinds.